Reitz Capital Advisors’s Pfizer PFE Stock Holding History

Reitz Capital Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-932	Closed	-$29K	–	94
2020 Q2	$29K	Buy	+932	New	+$31.7K	0.04%	80

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Reitz Capital Advisors's PFE Position: Q3 2020 in Review

Reitz Capital Advisors sold out of Pfizer (PFE) in Q3 2020, closing a stake of 932 shares — an estimated $29K sold.

Reitz Capital Advisors first reported a position in PFE in Q2 2020 and held it in 1 quarter. The position peaked at $29K in Q2 2020. 2,508 funds tracked by Wall St. Rank hold PFE as of Q3 2020.

Reitz Capital Advisors reported no remaining Pfizer position as of Q3 2020 after selling out during the quarter.
Reitz Capital Advisors sold 932 Pfizer shares in Q3 2020, an estimated $29K.
Reitz Capital Advisors first reported a position in Pfizer in Q2 2020 and held it in 1 quarter.
Reitz Capital Advisors's Pfizer position peaked at $29K in Q2 2020.
2,508 funds tracked by Wall St. Rank held Pfizer as of Q3 2020.

Based on Reitz Capital Advisors's 13F filing for Q3 2020, filed 19 Oct 2020.